404 related articles for article (PubMed ID: 18543809)
1. Rebuilding the R&D engine in big pharma.
Garnier JP
Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
[TBL] [Abstract][Full Text] [Related]
2. Helping science to succeed: improving processes in R&D.
Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
[TBL] [Abstract][Full Text] [Related]
3. Mastering the value chain. An interview with Mark Levin of Millennium Pharmaceuticals. Interview by David Champion.
Levin M
Harv Bus Rev; 2001 Jun; 79(6):108-15, 148. PubMed ID: 11408971
[TBL] [Abstract][Full Text] [Related]
4. A time for growth: an interview with Amgen CEO Kevin Sharer. Interview by Paul Hemp.
Sharer K
Harv Bus Rev; 2004; 82(7-8):66-74, 186. PubMed ID: 15241953
[TBL] [Abstract][Full Text] [Related]
5. No ordinary boot camp.
Tichy NM
Harv Bus Rev; 2001 Apr; 79(4):63-70, 166. PubMed ID: 11299694
[TBL] [Abstract][Full Text] [Related]
6. Strategy as revolution.
Hamel G
Harv Bus Rev; 1996; 74(4):69-82. PubMed ID: 10158475
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. A new mandate for human resources.
Ulrich D
Harv Bus Rev; 1998; 76(1):124-34. PubMed ID: 10176915
[TBL] [Abstract][Full Text] [Related]
9. To succeed in the long-term, focus on the middle-term.
Moore GA
Harv Bus Rev; 2007; 85(7-8):84-90, 192. PubMed ID: 17642127
[TBL] [Abstract][Full Text] [Related]
10. Keynote review: Is declining innovation in the pharmaceutical industry a myth?
Schmid EF; Smith DA
Drug Discov Today; 2005 Aug; 10(15):1031-9. PubMed ID: 16055019
[TBL] [Abstract][Full Text] [Related]
11. Advances in knowledge management for pharmaceutical research and development.
Torr-Brown S
Curr Opin Drug Discov Devel; 2005 May; 8(3):316-22. PubMed ID: 15892246
[TBL] [Abstract][Full Text] [Related]
12. Sustainable growth, the DuPont way.
Holliday C
Harv Bus Rev; 2001 Sep; 79(8):129-34, 162. PubMed ID: 11550629
[TBL] [Abstract][Full Text] [Related]
13. Restructuring the total quality way--corporate quality leaders share their experiences. Interview by Lisa M. O'Rourke.
Andreatis N; Arendt C
Qual Lett Healthc Lead; 1994 Feb; 6(1):13-7. PubMed ID: 10132209
[TBL] [Abstract][Full Text] [Related]
14. How the research-based industry approaches vaccine development and establishes priorities.
André FE
Dev Biol (Basel); 2002; 110():25-9. PubMed ID: 12477303
[TBL] [Abstract][Full Text] [Related]
15. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
Forster SP; Stegmaier J; Spycher R; Seeger S
Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
[TBL] [Abstract][Full Text] [Related]
16. The business against case revolution. An interview with Nestlé's Peter Brabeck. Interview by Sue Wetlaufer.
Brabeck P
Harv Bus Rev; 2001 Feb; 79(2):112-9, 157. PubMed ID: 11213685
[TBL] [Abstract][Full Text] [Related]
17. How should we support pharmaceutical innovation?
Grootendorst P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
[TBL] [Abstract][Full Text] [Related]
18. What really works.
Nohria N; Joyce W; Roberson B
Harv Bus Rev; 2003 Jul; 81(7):42-52, 116. PubMed ID: 12858710
[TBL] [Abstract][Full Text] [Related]
19. A more rational approach to new-product development.
Bonabeau E; Bodick N; Armstrong RW
Harv Bus Rev; 2008 Mar; 86(3):96-102, 134. PubMed ID: 18411967
[TBL] [Abstract][Full Text] [Related]
20. Ending the CEO succession crisis.
Charan R
Harv Bus Rev; 2005 Feb; 83(2):72-81, 147. PubMed ID: 15724575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
